CO6362013A2 - Derivados de rifamicina - Google Patents

Derivados de rifamicina

Info

Publication number
CO6362013A2
CO6362013A2 CO11078443A CO11078443A CO6362013A2 CO 6362013 A2 CO6362013 A2 CO 6362013A2 CO 11078443 A CO11078443 A CO 11078443A CO 11078443 A CO11078443 A CO 11078443A CO 6362013 A2 CO6362013 A2 CO 6362013A2
Authority
CO
Colombia
Prior art keywords
compounds
alkyl
hydroxyalkyl
hydrogen
antibacterial activity
Prior art date
Application number
CO11078443A
Other languages
English (en)
Inventor
Giuseppe Claudio Viscomi
Manuela Campana
Goffredo Rosini
Paolo Righi
Vincenzo Cannata
Mahena Folegatti
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of CO6362013A2 publication Critical patent/CO6362013A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)

Abstract

Se revelan compuestos que incluyen derivados de rifamicina que tienen actividad antibacteriana, en donde los compuestos tienen la siguiente fórmula general:en donde:R es hidrógeno o acetilo R1 y R2 se seleccionan, en forma independiente, entre el grupo conformado por hidrógeno, alquilo(C1-4), benciloxi, mono- y di-alquilamino(C1-3)alquilo(C1-4), alcoxi(C1-3), alquilo(C1-4), hidroximetilo, hidroxialquilo(C2-4), y nitro, o R1 y R2 tomados en forma conjunta con dos átomos de carbono consecutivos del núcleo piridina forman un anillo de benceno, en forma opcional, sustituido por uno o dos grupos metilo o etilo, y R3 es hidroxialquilo(C1-4). Asimismo, se describen los procesos para obtener estos compuestos.Los compuestos tienen actividad antibacteriana.
CO11078443A 2009-04-20 2011-06-22 Derivados de rifamicina CO6362013A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI2009A000653A IT1397617B1 (it) 2009-04-20 2009-04-20 Nuovi derivati della rifamicina

Publications (1)

Publication Number Publication Date
CO6362013A2 true CO6362013A2 (es) 2012-01-20

Family

ID=41228810

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11078443A CO6362013A2 (es) 2009-04-20 2011-06-22 Derivados de rifamicina

Country Status (27)

Country Link
US (2) US8318763B2 (es)
EP (1) EP2421869B1 (es)
JP (1) JP5661100B2 (es)
KR (1) KR101555860B1 (es)
CN (1) CN102405223A (es)
AR (1) AR076340A1 (es)
AU (1) AU2010240638B2 (es)
BR (1) BRPI1005979A8 (es)
CA (1) CA2743801C (es)
CL (1) CL2011002597A1 (es)
CO (1) CO6362013A2 (es)
DK (1) DK2421869T3 (es)
EA (1) EA020201B1 (es)
ES (1) ES2535327T3 (es)
HR (1) HRP20110437A2 (es)
IL (1) IL212942A (es)
IT (1) IT1397617B1 (es)
MA (1) MA33320B1 (es)
MX (1) MX338334B (es)
NZ (1) NZ595884A (es)
PL (1) PL2421869T3 (es)
PT (1) PT2421869E (es)
SG (1) SG171989A1 (es)
TN (1) TN2011000265A1 (es)
TW (1) TWI422372B (es)
UA (1) UA105775C2 (es)
WO (1) WO2010122436A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2895169A4 (en) * 2012-09-12 2016-02-24 Salix Pharmaceuticals Inc METHODS OF ADMINISTERING RIFAXIMINE WITHOUT PRODUCING ANTIBIOTIC RESISTANCE
CN103709177B (zh) * 2013-12-20 2016-02-24 武汉工程大学 利福霉素类沃尼妙林杂合抗生素及其制备方法
PT3546464T (pt) * 2014-05-12 2020-08-05 Alfasigma Spa Preparação e utilização da forma cristalina tau de rifaximina solvatada com degme
HUE054832T2 (hu) * 2017-06-26 2021-10-28 Biofer Spa Pirido-imidazo rifamicinszármazékok baktériumellenes szerként

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE751182A (fr) 1969-05-30 1970-11-03 Takeda Chemical Industries Ltd Procede de fabrication d'antibiotiques
SU465795A3 (ru) * 1972-05-05 1975-03-30 Группо Лепетит (Фирма) Способ получени рифамицина в.
US3847903A (en) * 1973-03-01 1974-11-12 Archifar Ind Chim Trentino Method for extracting and isolating rifamycin o from fermentation broths of rifamycins
CH571064A5 (en) * 1973-03-01 1975-12-31 Archifar Ind Chim Trentino Recovery of rieamycin from broths - by oxidn to an insol form
US4267274A (en) * 1973-04-26 1981-05-12 Gruppo Lepetit S.P.A. Streptomyces mediterranei mutant capable of production of rifamycin B
GB1470426A (en) * 1974-08-30 1977-04-14 Lepetit Spa Rifamycins
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin

Also Published As

Publication number Publication date
EA201190216A1 (ru) 2012-02-28
TN2011000265A1 (en) 2012-12-17
US8765778B2 (en) 2014-07-01
MX2011011026A (es) 2011-11-02
HK1163663A1 (en) 2012-09-14
US8318763B2 (en) 2012-11-27
IT1397617B1 (it) 2013-01-18
ES2535327T3 (es) 2015-05-08
EP2421869B1 (en) 2015-03-11
KR20120014110A (ko) 2012-02-16
EP2421869A1 (en) 2012-02-29
HRP20110437A2 (hr) 2011-09-30
EA020201B1 (ru) 2014-09-30
US20100267654A1 (en) 2010-10-21
NZ595884A (en) 2012-12-21
KR101555860B1 (ko) 2015-09-25
AU2010240638A1 (en) 2010-10-28
BRPI1005979A2 (pt) 2016-02-10
CL2011002597A1 (es) 2012-03-23
MA33320B1 (fr) 2012-06-01
US20130287692A1 (en) 2013-10-31
TWI422372B (zh) 2014-01-11
AR076340A1 (es) 2011-06-01
WO2010122436A1 (en) 2010-10-28
IL212942A (en) 2015-06-30
CA2743801A1 (en) 2010-10-28
SG171989A1 (en) 2011-07-28
AU2010240638B2 (en) 2014-06-05
BRPI1005979A8 (pt) 2017-12-26
JP2012524060A (ja) 2012-10-11
CA2743801C (en) 2017-03-07
ITMI20090653A1 (it) 2010-10-21
JP5661100B2 (ja) 2015-01-28
UA105775C2 (uk) 2014-06-25
CN102405223A (zh) 2012-04-04
PT2421869E (pt) 2015-04-29
DK2421869T3 (da) 2015-06-08
MX338334B (es) 2016-04-11
PL2421869T3 (pl) 2015-08-31
TW201039819A (en) 2010-11-16
IL212942A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
AR076340A1 (es) Derivados de rifamicina
MA34389B1 (fr) Nouvelles aminopyrazoloquinazolines
DOP2012000318A (es) Compuestos heterociclicos fusionados
SV2009003373A (es) COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5- FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA REF. AM102759
CU20180144A7 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
AR070221A1 (es) Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CL2016002942A1 (es) Nuevos derivados de pirazolina pirimidina y su uso como inhibidores de malt1
ES2607952T3 (es) Derivados tricíclicos de Pirazol Amina
MX2015011311A (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y analogos del mismo como inhibidores de atotaxina.
NI201000198A (es) Compuestos triazina como inhibidores mtor y quinasa p13.
MX2015007883A (es) Compuestos para protección de células.
PE20121048A1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
SV2010003459A (es) Derivados de pirimidina 934
EA201070876A1 (ru) Трициклические соединения, обладающие антагонистической активностью по отношению к кортикотропин-высвобождающему фактору, и содержащие их фармацевтические композиции
AR069607A1 (es) Inhibidores de la estearoil-coa desaturasa
CU20090064A7 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina
JO3143B1 (ar) مركبات تتراهيدرو بيرولو ثيازين
MX353190B (es) Derivados de isoquinolina y naftiridina.
CO2018010787A2 (es) Compuesto de griseofulvina
UY32635A (es) Derivados de bis-(sulfonilamino) en terapia 735

Legal Events

Date Code Title Description
FC Application refused